Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.041942619790151604 | N/A |
Market Cap | $264.99M | N/A |
Shares Outstanding | 6.32B | 12.08% |
Employees | 0 | N/A |
Shareholder Equity | 189.63M | 36.71% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -6.76 | N/A |
P/B Ratio | 1.40 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.1353 | N/A |
Earnings | 2023 | Change |
---|---|---|
Earnings | -$25.65M | N/A |
EPS | -0.0062 | N/A |
Earnings Yield | -0.1478 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $133.31M | N/A |
Total Debt | $374.42K | N/A |
Cash on Hand | $103.61M | N/A |
Debt to Equity | 0.0265 | -38.88% |
Cash to Debt | $276.71 | 86.55% |
Current Ratio | $27.23 | 77.70% |